Search

Human epidemiology and experimental animal data have provided the statistical association and biological information necessary to propose that aflatoxins are risk factors for human liver cancer. As liver cancer causes at least 200,000 deaths per year, prevention measures must be developed to ameliorate this nearly always fatal disease. Preventive strategies will be facilitated by the identification of individuals at high risk. It is the goal of the molecular dosimetry field to provide facile and accurate biomarkers to identify people at high risk for carcinogen exposure and consequent adverse health effects. We have developed methods to defect the major aflatoxin DNA adduct, aflatoxin N7-guanine (AFB-N7-guanine), in urine, examined the dose-response characteristics in people living in China and The Gambia, and have found an excellent association of this biomarker with exposure. In addition to exposure studies in people, our laboratories have monitored AFB-N7-guanine excretion in the urine of rats whose risk for developing cancer has been modulated with dietary chemoprotective agents such that independent groups of animals receiving the same dosage of aflatoxin B1 were at either high or low risk for tumorigenesis. The production of DNA damage by aflatoxins is not the exclusive mechanism for liver cancer. Many other factors, including hepatitis B virus, cell proliferation, and nutritional status, can exert strong modification effects in human disease. Thus, molecular epidemiological investigations that examine only one biomarker may greatly underestimate or overestimate the risk for an individual.(ABSTRACT TRUNCATED AT 250 WORDS)

A polyclonal rabbit antibody preparation against aflatoxin B1 (AFB1), produced by immunization with a bovine serum albumin-AFB1 conjugate, has been used to develop an enzyme-linked immunosorbent assay (ELISA). AFB1-ovalbumin, obtained by reacting either AFB1-8,9-dichloride or -8,9-dibromide with ovalbumin, was used to coat each well of a polyvinyl microtitre dish. Rabbit antibody, diluted 1:100 000, was added to each well and left to attach for 90 min, then the excess was washed off with phosphate-buffered saline/Tween. Anti-rabbit IgG coupled to peroxidase was then added, left for 90 min and the excess washed away. Residual peroxidase activity was assayed using tetramethylbenzidine as substrate; the reaction was quenched at the end of the 15-min incubation period with 2 N sulfuric acid. Inhibitor studies to assay AFB1 and related compounds in urine involved prior incubation of the diluted anti-AFB1 antibody with inhibitor for 60 min at 37 degrees C, prior to dispensing into the multi-well plates. Inhibitor studies with AFB1 showed inhibition over a concentration range of 10(-1) to 10(-5) micrograms/ml. The minimum detectable concentration was approximately 10(-5) micrograms/ml (0.032 pmol/ml). Anti-AFB1 antibody was also inhibited by iro-AFB1-DNA, one of the forms of AFB1-DNA, as well as by AFB1-guanine. Undiluted urine from normal subjects inhibited antibody binding to plates; this inhibition could be prevented by either dilution or extraction procedures.(ABSTRACT TRUNCATED AT 250 WORDS)